Transformative bispecific antibody technology

F-star is developing a promising pipeline of immuno-oncology therapies with its innovative bispecific antibody technology, which is ideally suited to uncover novel combinatorial biology. To download the full article, please sign in.

Go to the profile of F-star
Nov 12, 2015
Page of
Go to the profile of F-star


F-star Biotechnology Ltd is an immuno-oncology focused biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve the standard of care for patients.

Comments are disabled